GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » FCF Yield %

CPP (Cancer Prevention Pharmaceuticals) FCF Yield % : 0.00 (As of Jun. 14, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cancer Prevention Pharmaceuticals's Trailing 12-Month Free Cash Flow is $0.56 Mil, and Market Cap is $0.00 Mil. Therefore, Cancer Prevention Pharmaceuticals's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's FCF Yield % or its related term are showing as below:


CPP's FCF Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.11
* Ranked among companies with meaningful FCF Yield % only.

Cancer Prevention Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2016 was 32.18%.


Cancer Prevention Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals FCF Yield % Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
FCF Yield %
- - -

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
FCF Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Cancer Prevention Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's FCF Yield % falls into.


;
;

Cancer Prevention Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cancer Prevention Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2015 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-2.915 / 0
=N/A%

Cancer Prevention Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2016 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0.334 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Prevention Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cancer Prevention Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals Headlines